1
|
Krustrup P, Williams CA, Mohr M, Hansen PR, Helge EW, Elbe AM, de Sousa M, Dvorak J, Junge A, Hammami A, Holtermann A, Larsen MN, Kirkendall D, Schmidt JF, Andersen TR, Buono P, Rørth M, Parnell D, Ottesen L, Bennike S, Nielsen JJ, Mendham AE, Zar A, Uth J, Hornstrup T, Brasso K, Nybo L, Krustrup BR, Meyer T, Aagaard P, Andersen JL, Hubball H, Reddy PA, Ryom K, Lobelo F, Barene S, Helge JW, Fatouros IG, Nassis GP, Xu JC, Pettersen SA, Calbet JA, Seabra A, Rebelo AN, Figueiredo P, Póvoas S, Castagna C, Milanovic Z, Bangsbo J, Randers MB, Brito J. The "Football is Medicine" platform-scientific evidence, large-scale implementation of evidence-based concepts and future perspectives. Scand J Med Sci Sports 2018; 28 Suppl 1:3-7. [PMID: 29917263 DOI: 10.1111/sms.13220] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- P Krustrup
- Department of Sports Science and Clinical Biomechanics, SDU Sport and Health Sciences Cluster (SHSC), Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
| | - C A Williams
- CHERC, Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, Exeter, UK
| | - M Mohr
- University of Faroe Islands, Torshavn, Faroe Islands
| | - P R Hansen
- Department of Cardiology, Gentofte University Hospital, Hellerup, Denmark
| | - E W Helge
- Department of Nutrition, Exercise and Sports (NEXS), University of Copenhagen, Copenhagen, Denmark
| | - A-M Elbe
- Universitat Leipzig, Leipzig, Germany
| | - M de Sousa
- Laboratory of Medical Investigation LIM-18, Endocrinology Division, School of Medicine, University of São Paulo, São Paulo, Brazil
| | - J Dvorak
- Spine Unit, Schulthess Clinic, Zurich, Switzerland
| | - A Junge
- Medical School Hamburg, University of Applied Sciences, Faculty of Health Sciences, Hamburg, Germany
| | - A Hammami
- Laboratory of Physiology, Faculty of Medicine of Sousse, University of Sousse, Benarous, Tunisia
| | - A Holtermann
- National Research Centre for the Working Environment, Copenhagen, Denmark
| | - M N Larsen
- Department of Sports Science and Clinical Biomechanics, SDU Sport and Health Sciences Cluster (SHSC), Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
| | - D Kirkendall
- James R. Urbaniak, Sport Sciences Institute, Duke University Medical Center, Durham, NC, USA
| | - J F Schmidt
- Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark
| | - T R Andersen
- Department of Sports Science and Clinical Biomechanics, Faculty of Health Sciences, University of Southern Denmark, Odense M, Denmark
| | - P Buono
- Department of Movement Sciences and Wellness, University Parthenope, Napoli, Italy
| | - M Rørth
- Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, UK
| | - D Parnell
- Department of Economics, Policy & International Business, Manchester Metropolitan University, Manchester, UK
| | - L Ottesen
- Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark
| | - S Bennike
- Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark
| | - J J Nielsen
- Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark
| | - A E Mendham
- Non-communicable Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa
| | - A Zar
- Department of Sport Science, Jahrom University, Jahrom, Iran
| | - J Uth
- The University Hospitals Centre for Health Care Research, Copenhagen University Hospital, Copenhagen, Denmark
| | - T Hornstrup
- Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark
| | - K Brasso
- Department of Urology, Copenhagen Prostate Cancer Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
| | - L Nybo
- NEXS, UCPH, Copenhagen, Denmark
| | - B R Krustrup
- Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark
| | - T Meyer
- Institute of Sports and Preventive Medicine, Saarland University, Germany
| | - P Aagaard
- Department of Sports Science and Clinical Biomechanics, SDU Sport and Health Sciences Cluster (SHSC), Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
| | - J L Andersen
- Institute of Sports Medicine Copenhagen, Copenhagen, Denmark
| | - H Hubball
- Department of Curriculum and Pedagogy, University of British Columbia, Vancouver, Canada
| | | | - K Ryom
- Department of Public Health, Aarhus University, Aarhus C, Denmark
| | - F Lobelo
- Hubert Department of Global Health, Rollins School of Public Health and Exercise is Medicine Global Research and Collaboration Center, Atlanta, Georgia, USA
| | - S Barene
- Department of Public Health, Faculty of Social and Health Sciences, Inland Norway University of Applied Sciences, Elverum, Norway
| | - J W Helge
- Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - I G Fatouros
- School of Physical Education and Sport Sciences, University of Thessaly, Trikala, Greece
| | | | - J C Xu
- China Institute of Sport Science, Beijing, China
| | - S A Pettersen
- School of Sport Sciences, UiT The Arctic Uniiversity of Norway, Tromsø, Norway
| | - J A Calbet
- Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
| | - A Seabra
- Portugal Football School, Portuguese Football Federation, Portugal
| | - A N Rebelo
- Faculdade de Desporto, Universidade do Porto, Porto, Portugal
| | - P Figueiredo
- Portugal Football School, Portuguese Football Federation, Portugal
| | - S Póvoas
- Research Center in Sports Sciences, Health Sciences and Human Development (CIDESD) University Institute of Maia (ISMAI), Maia, Portugal
| | - C Castagna
- School of Sport and Exercise Sciences, University of Rome Tor Vergata, Rome, Italy.,Fitness Training and Biomechanics Laboratory, Italian Footbal Association (FIGC), Technical Department, Coverciano, Italy
| | - Z Milanovic
- Faculty of Sport and Physical Education, University of Nis, Nis, Serbia.,Science and Research Centre Koper, Institute for Kinesiology Research, Koper, Slovenia
| | - J Bangsbo
- Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark
| | - M B Randers
- Department of Sports Science and Clinical Biomechanics, SDU Sport and Health Sciences Cluster (SHSC), Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
| | - J Brito
- Portugal Football School, Portuguese Football Federation, Portugal
| |
Collapse
|
2
|
Møller TK, Nielsen TT, Andersen R, Lundager I, Hansen HF, Ottesen L, Krustrup P, Randers MB. Health Effects of 12 Weeks of Team-Sport Training and Fitness Training in a Community Health Centre for Sedentary Men with Lifestyle Diseases. Biomed Res Int 2018; 2018:1571807. [PMID: 29888250 PMCID: PMC5977017 DOI: 10.1155/2018/1571807] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Revised: 02/26/2018] [Accepted: 03/08/2018] [Indexed: 12/17/2022]
Abstract
This study compares the effects of team-sport training, for sedentary men with lifestyle diseases, with fitness training in a pragmatic set-up in a community health centre (CHC). Thirty-two men in the fitness group (FiG) and 36 men in the team-sport group (TsG) completed the training and trained for 60-90 min, two times/week for 12-16 weeks. In FiG and TsG, mean heart rate (HR) during training was 73.2% and 74.5% of HRmax, respectively. Percentage of training time above 90%HRmax was 6 ± 9% and 10 ± 15% and the percentage of participants who spent > 10% of total training time with HR > 90%HRmax was 20% and 41%, in FiG and TsG, respectively. In FiG, total fat mass was reduced by 3.5% (P < 0.01), while performance in the 6 min walking test (6MWT) increased by 11% (P < 0.001). In TsG, total fat mass was reduced by 2.2% (P < 0.01), while 6MWT performance improved by 5% (P < 0.05). Between-group differences were observed for systolic BP (P = 0.041) and mean arterial pressure (P = 0.050) in favour of TsG and for sit-to-stand test (P = 0.031) in favour of FiG. In conclusion, small-sided team sport is a worthy alternative to fitness training since the overall health effects are comparable, for example, improved balance and reduced fat mass. Team sport elicits high heart rates and improves cardiovascular health by reducing blood pressure, while fitness training improves sit-to-stand test performance related to activity of daily living.
Collapse
Affiliation(s)
- T. K. Møller
- Department of Sports Science and Clinical Biomechanics, SDU Sport and Health Sciences Cluster (SHSC), University of Southern Denmark, Odense, Denmark
| | - T.-T. Nielsen
- Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark
- University College Copenhagen, Copenhagen, Denmark
| | - R. Andersen
- Prevention Centre Nørrebro, Copenhagen, Denmark
| | - I. Lundager
- Department of Sports Science and Clinical Biomechanics, SDU Sport and Health Sciences Cluster (SHSC), University of Southern Denmark, Odense, Denmark
| | - H. F. Hansen
- Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark
| | - L. Ottesen
- Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark
| | - P. Krustrup
- Department of Sports Science and Clinical Biomechanics, SDU Sport and Health Sciences Cluster (SHSC), University of Southern Denmark, Odense, Denmark
- Sport and Health Sciences, University of Exeter, Exeter, UK
| | - M. B. Randers
- Department of Sports Science and Clinical Biomechanics, SDU Sport and Health Sciences Cluster (SHSC), University of Southern Denmark, Odense, Denmark
| |
Collapse
|
4
|
Milojkovic Kerklaan B, Slater S, Flynn M, Greystoke A, Witteveen PO, Megui-Roelvink M, de Vos F, Dean E, Reyderman L, Ottesen L, Ranson M, Lolkema MPJ, Plummer R, Kristeleit R, Evans TRJ, Schellens JHM. A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. Invest New Drugs 2016; 34:329-37. [PMID: 27039386 DOI: 10.1007/s10637-016-0344-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Accepted: 03/11/2016] [Indexed: 01/13/2023]
Abstract
UNLABELLED Introduction E7820 is an orally administered sulfonamide that inhibits alfa-2-integrin mRNA expression. Pre-clinically E7820 showed tumor anti-angiogenic effects in various tumor cell lines and xenograft mouse models. Human daily dosing of 100 mg QD had previously been shown to be safe and tolerable. Methods The study consisted of two parts: Part A (food effect) and Part B (determination of maximum tolerated dose (MTD) for bi-daily (BID) dosing). E7820 dosing started at 50 mg BID with planned escalation to 60, 80 and 100 mg BID every 28 days. Results Fifteen patients were enrolled in Part A and 26 in Part B. The most frequent adverse events of all grades were constipation, diarrhea, nausea, and fatigue while anemia, neutropenia, and fatigue were most frequent grade ≥3 toxicities. At dose-level 60 mg BID, two patients experienced dose-limiting toxicities (grade 3 neutropenic sepsis and grade 4 neutropenia). Therefore the recommended dose (RD) was 50 mg BID. Food had no effect on E7820 exposure. E7820 exposure following twice daily administration was dose-proportional. Expression of platelet integrin-α2 measured as a response biomarker in Part B, generally decreased by a median 7.7 % from baseline following treatment with 50 mg BID E7820. Reduction was most pronounced within 1-week post treatment. The median duration of treatment was median 54, range 20-111 days. The best overall response in any treatment group was stable disease (SD): 23.1 % in Part A (100 mg QD); at the RD 66.7 % (12 of 18 patients) and 40 % in the 60 mg BID group in Part B. CONCLUSIONS Food had no effect on E7820 exposure. A dose of 50 mg BID was considered the MTD. Treatment with E7820 is safe and tolerable with 2/3 of patients (66.7 %) at MTD having SD as their best response.
Collapse
Affiliation(s)
- B Milojkovic Kerklaan
- Department of Clinical Pharmacology, Division of Internal Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands
| | - S Slater
- The Beatson West of Scotland Cancer Centre, University Glasgow, Glasgow, UK
| | - M Flynn
- University College London Hospital, London, United Kingdom
| | - A Greystoke
- The Christie NHS Foundation Trust / University of Manchester, Manchester, UK
| | - P O Witteveen
- Department of Medical Oncology, Cancer Center, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - M Megui-Roelvink
- Department of Clinical Pharmacology, Division of Internal Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands
| | - F de Vos
- Department of Medical Oncology, Cancer Center, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - E Dean
- The Christie NHS Foundation Trust / University of Manchester, Manchester, UK
| | | | | | - M Ranson
- The Christie NHS Foundation Trust / University of Manchester, Manchester, UK
| | - M P J Lolkema
- Department of Medical Oncology, Cancer Center, University Medical Centre Utrecht, Utrecht, The Netherlands
- Erasmus Medical Center Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands
| | - R Plummer
- Sir Bobby Robson Cancer Trials Research Centre Newcastle, Newcastle, UK
| | - R Kristeleit
- University College London Hospital, London, United Kingdom
| | - T R J Evans
- The Beatson West of Scotland Cancer Centre, University Glasgow, Glasgow, UK
| | - J H M Schellens
- Department of Clinical Pharmacology, Division of Internal Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
- Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.
| |
Collapse
|